Interventional Cardiology Research and Innovation at UPMC Children's Hospital of Pittsburgh

Innovative Contributions to the Field of Congenital Heart Disease

• 1977: Sang Park, MD, develops the Park Blade Septostomy Catheter and blade atrial septostomy procedure. They enlarge openings in the heart for treatment of infants with cyanotic CHD.
• 1990s: Early adoption of transcatheter ASD device closure, including taking part in the pivotal clinical trial for the Amplatzer septal occluder device.
• 2007 to Present: Consistent involvement in landmark multicenter clinical device trials. Continued national/global quality improvement work through the C3PO, IMPACT and CCRC registries.
• 2010: First U.S. transcatheter pulmonary valve (Melody TPV) implant by Jacqueline Kreutzer, MD, after FDA approval.
• 2020: Pioneered clinical outcomes research in CHD leading to innovations in management of cyanotic neonates. Bryan Goldstein, MD, co-founded and leads the Congenital Cardiac Research Collaborative (CCRC).
• Present day: Among the first in the world after FDA approval to implant the Harmony TPV (2021) and the Alterra Adaptive Prestent + Sapien 3 THV (2022) to restore pulmonary valve function after childhood intervention for CHD 

Heart Cath Research from Experts at UPMC Children's Hospital of Pittsburgh

We take part in a wide range of catheterization research, including invasive physiological assessment of and interventional treatments for CHD.

View recent publications from members of our team:

• Comparative Costs of Management Strategies for Neonates With Symptomatic Tetralogy of Fallot. Goldstein BH, et al.  J Am Coll Cardiol. 2022 Mar 29;79(12):1170-1180.
• Virtual Transcatheter Interventions for Peripheral Pulmonary Artery Stenosis in Williams and Alagille Syndromes. Kreutzer J, et al. J Am Heart Assoc. 2022 Mar 15;11(6):e023532.
• Reintervention and Survival After Transcatheter Pulmonary Valve Replacement. Goldstein BH, et al.  J Am Coll Cardiol. 2022 Jan 4;79(1):18-32.
• Procedural Risk in Congenital Cardiac Catheterization (PREDIC3T). Goldstein B, Trucco S, et al. J Am Heart Assoc. 2022 Jan 4;11(1):e022832.
• Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement. Goldstein BH, et al. J Am Coll Cardiol. 2021 Aug 10;78(6):575-589.
• Comparison of the investigational device exemption and post-approval trials of the Melody TPV. Kreutzer J, et al. Catheter Cardiovasc Interv. 2021 Aug 1;98(2):E262-E274.
• Comparison of management strategies for neonates with symptomatic tetralogy of Fallot and weight <2.5 kg. Goldstein BH, Congenital Cardiac Research Collaborative Investigators, et al. J Thorac Cardiovasc Surg. 2022 Jan;163(1):192-207.e3.
• Comparison of Management Strategies for Neonates With Symptomatic Tetralogy of Fallot. Goldstein BH, et al. J Am Coll Cardiol. 2021 Mar 2;77(8):1093-1106.
• Transcatheter Intervention for Congenital Defects Involving the Great Vessels. JACC Review Topic of the Week. Goldstein BH, Kreutzer J. J Am Coll Cardiol. 2021 Jan 5;77(1):80-96.
• Transcatheter Pulmonary Valve Replacement With the Sapien Prosthesis. Goldstein BH, et al. J Am Coll Cardiol. 2020 Dec 15;76(24):2847-2858.
• Outcomes After Transcatheter Reintervention for Dysfunction of a Previously Implanted Transcatheter Pulmonary Valve. Kreutzer J, et al. JACC Cardiovasc Interv. 2020 Jul 13;13(13):1529-1540.
• Longitudinal Improvements in Radiation Exposure in Cardiac Catheterization for Congenital Heart Disease. A Prospective Multicenter C3PO-QI Study. Goldstein B, Trucco S, et al. Circ Cardiovasc Interv. 2020 May;13(5):e008172.
• Resource Allocation and Decision Making for Pediatric and Congenital Heart Cath During the Novel Coronavirus SARS-CoV-2 (COVID-19) Pandemic. A U.S. Multicenter Perspective. Goldstein BH, et al. J Invasive Cardiol. 2020 May;32(5):E103-E109.
• Adverse Events, Radiation Exposure, and Reinterventions Following Transcatheter Pulmonary Valve Replacement. Goldstein BH, Kreutzer J, et al. J Am Coll Cardiol. 2020 Feb 4;75(4):363-376.
• ASSURED clinical study: New GORE® CARDIOFORM ASD occluder for transcatheter closure of atrial septal defect. Goldstein BH, et al. Catheter Cardiovasc Interv. 2020 Jun 1;95(7):1285-1295.
• Use of carotid and axillary artery approach for stenting the patent ductus arteriosus in infants with ductal-dependent pulmonary blood flow. A multicenter study from the congenital catheterization research collaborative. Goldstein BH, et al. Catheter Cardiovasc Interv. 2020 Mar 1;95(4):726-733.
• Relationship Between Time to Left Atrial Decompression and Outcomes in Patients Receiving Venoarterial ECMO Support. A Multicenter Pediatric Interventional Cardiology Early-Career Society Study. Trucco SM, Goldstein BH, et al. Pediatr Crit Care Med. 2019 Aug;20(8):728-736.
• Post-op Transcatheter Interventions in Children Undergoing Congenital Heart Surgery.Goldstein BH, et al. Circ Cardiovasc Interv. 2019 Jun;12(6):e007853.
• Endocarditis After Transcatheter Pulmonary Valve Replacement. Kreutzer J, et al. J Am Coll Cardiol. 2018 Dec 4;72(22):2717-2728.
• Results of the combined U.S. multicenter postapproval study of the Nit-Occlud PDA device for percutaneous closure of patent ductus arteriosus. Goldstein BH, et al. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):645-651.
• Covered CP Stent for Treatment of Right Ventricular Conduit Injury During Melody TPV Replacement. Goldstein BH, et al. Circ Cardiovasc Interv. 2018 Oct;11(10):e006598.
• Safety and Feasibility of Melody TPV Replacement in the Native Right Ventricular Outflow Tract. A Multicenter Pediatric Heart Network Scholar Study. Goldstein BH, et al. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1642-1650.
• Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly. Goldstein BH, et al. Am J Cardiol. 2018 Jan 15;121(2):262-268.
• Comparison Between Patent Ductus Arteriosus Stent and Modified Blalock-Taussig Shunt as Palliation for Infants With Ductal-Dependent Pulmonary Blood Flow. Insights From the Congenital Catheterization Research Collaborative. Goldstein BH, et al. Circulation. 2018 Feb 6;137(6):589-601.

Contact the Interventional Cardiology Program at UPMC Children's 

• Call 412-692-8763.
• Email cardiaccath@upmc.edu.